tisagenlecleucel
novartis
['tisa-cel', 'elara', 'lymsm', 'lymphoma', 'follicular', 'tisagenlecleucel']
updated elara trial of tisa-cel in r/r follicular lymphoma. very good response rates in high-risk fl, with very long dor in patients with cr (but not pr). pfs and os not reached (inferior pfs with pr). interesting: higher tumor burden = inferior pfs and dor. #ash22 #lymsm 
#lymsm & #mmsm hematologist & patient-reported outcomes researcher @CUHematology. Founder of https://t.co/kN6qeGXfg5, @inTrainingDoc & @inHouseMag. ??????